# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Edward White reiterates Adicet Bio (NASDAQ:ACET) with a Buy and maintains $10 price target.
Canaccord Genuity analyst John Newman maintains Adicet Bio (NASDAQ:ACET) with a Buy and maintains $19 price target.
HC Wainwright & Co. analyst Edward White reiterates Adicet Bio (NASDAQ:ACET) with a Buy and maintains $10 price target.
HC Wainwright & Co. analyst Edward White reiterates Adicet Bio (NASDAQ:ACET) with a Buy and maintains $10 price target.
HC Wainwright & Co. analyst Edward White reiterates Adicet Bio (NASDAQ:ACET) with a Buy and maintains $10 price target.
Fast Track Designation is a process designed to facilitate the development and expedite the review of drugs intended to treat s...